GRK 3 Activators
GRK3 activators constitute a class of chemicals strategically selected for their ability to modulate G protein-coupled receptor kinase 3 (GRK3) activity. These chemicals predominantly act through indirect mechanisms, influencing specific signaling pathways to enhance GRK3-mediated desensitization of G protein-coupled receptors (GPCRs). Carvedilol, a non-selective beta-blocker, exemplifies this class by indirectly activating GRK3 through the modulation of β-adrenergic signaling. By inhibiting β-adrenergic receptors, carvedilol disrupts the negative feedback loop on GRK3, leading to enhanced phosphorylation and desensitization of GPCRs, a pivotal process in cellular signaling regulation.
The angiotensin II receptor antagonist losartan is another member of the GRK3 activator class. Through blockade of angiotensin II receptors, losartan interferes with the angiotensin II signaling pathway, indirectly promoting GRK3 activity. This effect results in heightened GRK3-mediated desensitization of GPCRs, contributing to the fine-tuning of cellular responses. Salmeterol, a long-acting beta2-adrenergic agonist, similarly impacts the β-adrenergic pathway, sustaining activation of β2-adrenergic receptors and enhancing GRK3-mediated desensitization of GPCRs. The GRK3 activators described in this class exhibit diverse pharmacological profiles, including beta-blockers, receptor antagonists, and agonists. Their commonality lies in their ability to modulate cellular signaling cascades, indirectly enhancing GRK3 function in the regulation of GPCR signaling. This nuanced approach highlights the intricate regulatory network involving GRK3 and provides insights into potential avenues for the development of pharmacological interventions targeting GPCR desensitization.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Carvedilol, a non-selective beta-blocker, indirectly activates GRK3 by modulating the β-adrenergic signaling pathway. By inhibiting β-adrenergic receptors, carvedilol reduces receptor phosphorylation and desensitization, indirectly promoting GRK3 activity in the regulation of G protein-coupled receptor (GPCR) signaling. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Losartan, an angiotensin II receptor antagonist, indirectly activates GRK3 by impacting the angiotensin II signaling pathway. By blocking angiotensin II receptors, losartan disrupts the negative feedback loop on GRK3, leading to enhanced GRK3-mediated desensitization of GPCRs and downstream signaling pathways. | ||||||
Salmeterol | 89365-50-4 | sc-224277 sc-224277A | 10 mg 50 mg | $186.00 $562.00 | 1 | |
Salmeterol, a long-acting beta2-adrenergic agonist, indirectly activates GRK3 through stimulation of the β-adrenergic pathway. By promoting sustained β2-adrenergic receptor activation, salmeterol enhances GRK3-mediated phosphorylation and desensitization, contributing to the regulation of GPCR signaling cascades. | ||||||
Nebivolol | 99200-09-6 | sc-279910 | 100 mg | $803.00 | 1 | |
Nebivolol, a selective beta1-adrenergic receptor antagonist with nitric oxide-potentiating vasodilatory effects, indirectly activates GRK3. By blocking beta1-adrenergic receptors, nebivolol disrupts the negative regulation on GRK3, leading to enhanced GRK3-mediated desensitization of GPCRs and modulation of downstream signaling pathways. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, a non-selective beta-adrenergic agonist, indirectly activates GRK3 by stimulating the β-adrenergic signaling pathway. Through increased activation of beta-adrenergic receptors, isoproterenol enhances GRK3-mediated phosphorylation and desensitization, influencing GPCR signaling and downstream cellular responses. | ||||||
Alprenolol | 13655-52-2 | sc-507469 | 50 mg | $130.00 | ||
Alprenolol, a non-selective beta-adrenergic antagonist, indirectly activates GRK3 by inhibiting beta-adrenergic receptors. By blocking beta-adrenergic receptors, alprenolol disrupts the negative feedback loop on GRK3, leading to enhanced GRK3-mediated desensitization of GPCRs and modulation of downstream signaling pathways. | ||||||
Metoprolol Tartrate | 56392-17-7 | sc-205751 sc-205751A | 5 g 25 g | $107.00 $243.00 | 3 | |
Metoprolol, a selective beta1-adrenergic receptor antagonist, indirectly activates GRK3. By inhibiting beta1-adrenergic receptors, metoprolol disrupts the negative regulation on GRK3, leading to enhanced GRK3-mediated desensitization of GPCRs and modulation of downstream signaling pathways. | ||||||
Pindolol | 13523-86-9 | sc-204847 sc-204847A | 100 mg 1 g | $194.00 $760.00 | ||
Pindolol, a non-selective beta-adrenergic antagonist and partial agonist, indirectly activates GRK3 by modulating beta-adrenergic receptors. By acting as a partial agonist, pindolol influences beta-adrenergic receptor activation, leading to enhanced GRK3-mediated phosphorylation and desensitization of GPCRs, contributing to the modulation of downstream signaling cascades. | ||||||
Amlodipine | 88150-42-9 | sc-200195 sc-200195A | 100 mg 1 g | $74.00 $166.00 | 2 | |
Amlodipine, a calcium channel blocker, indirectly activates GRK3 by modulating calcium-dependent signaling pathways. By inhibiting calcium influx through voltage-gated channels, amlodipine disrupts the negative regulation on GRK3, leading to enhanced GRK3-mediated desensitization of GPCRs and modulation of downstream signaling pathways. | ||||||